Gilead Drug Fails AIDS Prevention Trial

4/18/11Follow @xconomy

Researchers have halted a study of Gilead Sciences’ emtricitabine tenofovir (Truvada) after it failed to show in a study that it can help prevent HIV infections among women in Africa, according to a report from the Associated Press. The finding was disappointing, the AP notes, because a previous study showed that the drug from Foster City, CA-based Gilead (NASDAQ: GILD) was able to prevent HIV infections in gay and bisexual men when it was given with condoms, counseling, and other prevention services.

By posting a comment, you agree to our terms and conditions.

  • Pingback: AIDS prevention pill study halted; no benefit seen – The Associated Press

  • James

    “was able to prevent HIV infections in gay and bisexual men when it was given with condoms”. Well duh! Did any of these geniuses ever consider the possibility that it was the condoms that provided protection?

  • Henry

    It’s been 30 years! We are long overdue for a cure! Please support re:solve AIDS and the Chronic Disease Fund. resolvefromcdf.org